Romin Bonakdar

Romin Bonakdar practices at Durham Nephrology Associates PA in Durham, North Carolina.

Romin Bonakdar's NPI, 1003236787, was assigned on April 22, 2014. Romin Bonakdar graduated from University of North Carolina at Chapel Hill School of Medicine in 2014. Romin Bonakdar holds North Carolina license 2017-00882.

Romin Bonakdar's primary practice is Durham Nephrology Associates PA, at 4419 Ben Franklin Blvd, Durham, NC 27704 in Durham County. The practice phone is (919) 477-3005.

Romin Bonakdar's primary practice is Durham Nephrology Associates PA in Durham, North Carolina. Romin Bonakdar is also affiliated with Duke Regional Hospital. The medical group on file is Durham Nephrology Associates. Dmand AI also links Romin Bonakdar to 1 more hospital, 3 dialysis centers and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Romin Bonakdar practices, 6 sites in all. Vendor and product names are available with a free account.

Nephrology is Romin Bonakdar's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Romin Bonakdar is board certified in internal medicine by the American Board of Internal Medicine. Romin Bonakdar is licensed in North Carolina.

CMS data shows 1,843 Medicare services from Romin Bonakdar across 17 procedure codes in 2024, for 367 Medicare patients. Medicare paid $145,439 for them.

CMS counts 367 Medicare patients who saw Romin Bonakdar in 2024. The largest group is 65 to 74, with 128 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 28% are also on Medicaid. Their average risk score is 5.05, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Romin Bonakdar's median patient age at 70, with 47% women.

In 2024, Romin Bonakdar wrote 1,783 Medicare Part D claims for 306 patients. 83% of them were for generic drugs. CMS names the drug for 1,481 of them, across 45 drugs with 11 or more claims each, at $303,119 in total drug cost. In 2023, CMS named 1,295 claims across 40 drugs.

Romin Bonakdar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Romin Bonakdar as offering telehealth.

CMS Open Payments shows 161 general payments to Romin Bonakdar from 23 drug and device companies from 2020 to 2025. Food and beverage make up the largest share, 98% of the total. Fresenius USA Marketing, Inc. paid the most, $386.

Romin Bonakdar graduated from University of North Carolina at Chapel Hill School of Medicine in 2014.